Max Liebo, MD
Cardiovascular Disease · Maywood, ILNPI 1306082094
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,614 of the $2,430 with a category attached, or 66.4%. Abiomed accounts for 66.7% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $1,144, 9.2 times the $125 reported in 2019.
Across 50 payments — averaging $48.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$2K
- Abbott$375
- Akcea Therapeutics, Inc.$133
- Cvrx, Inc.$74
- Novartis$68
- Livanova USA, Inc.$31
- plus $128 from 6 others
Across 23 payments — averaging $2313.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$39K
- Ionis Pharmaceuticals, Inc.$11K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
What the payments were for
- Travel & lodging$66828%
- Food & beverage$1,61466%
- Education$1476%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 19 | $1,621 |
| Abbott | 12 | $375 |
| Akcea Therapeutics, Inc. | 2 | $133 |
| Cvrx, Inc. | 7 | $74 |
| Novartis | 3 | $68 |
| Livanova USA, Inc. | 1 | $31 |
| Lexicon Pharmaceuticals, Inc. | 1 | $31 |
| Boehringer Ingelheim | 1 | $23 |
| Pfizer | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,430 in reported general payments places this provider in the 60th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 78 | $2,266,627 |
| WainuaEplontersen Sodium | 21 | $882,111 |
| EntrestoSacubitril/Valsartan | 172 | $290,549 |
| JardianceEmpagliflozin | 111 | $134,607 |
| FarxigaDapagliflozin Propanediol | 87 | $118,464 |
| EliquisApixaban | 63 | $81,002 |
| Everolimus | 29 | $30,683 |
| CorlanorIvabradine Hcl | 11 | $19,217 |
| Envarsus XrTacrolimus | 13 | $18,841 |
| Sirolimus | 29 | $10,667 |
| Tacrolimus | 48 | $8,642 |
| Mycophenolate Mofetil | 32 | $4,649 |
| Bumetanide | 46 | $4,113 |
| Metoprolol Succinate | 200 | $3,749 |
| Eplerenone | 33 | $3,154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $21 | $2,347,629141 claims |
| NovartisEntresto | $68 | $290,549172 claims |
| Boehringer IngelheimJardiance | $23 | $134,607111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Maywood
- Niraj VarmaMaywood$522K
- Mark RabbatMaywood$363K
- Smit VasaiwalaMaywood$264K
- Clifford KavinskyMaywood$260K
- Gregory MacalusoMaywood$165K
- Dana JohnsonMaywood$104K
- Erin CoglianeseMaywood$36K
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.